139 related articles for article (PubMed ID: 20959069)
41. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR
Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786
[TBL] [Abstract][Full Text] [Related]
42. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
43. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA.
Isernhagen A; Schilling D; Monecke S; Shah P; Elsner L; Walter L; Multhoff G; Dressel R
Immunogenetics; 2016 Feb; 68(2):109-23. PubMed ID: 26585323
[TBL] [Abstract][Full Text] [Related]
44. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
45. [Expression and abscission of activated receptors and their ligands on/from NK cells in peripheral blood of patients with acute leukemia].
Fang XC; Liu HL; Sun ZM; Gui L; Geng LQ; Wang XB; Zhou M; Wang ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):436-40. PubMed ID: 20416183
[TBL] [Abstract][Full Text] [Related]
46. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
47. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
48. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
49. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
50. The decrease in NKG2D+ Natural Killer cells in peripheral blood of patients with metastatic colorectal cancer.
Gharagozloo M; Kalantari H; Rezaei A; Maracy MR; Salehi M; Bahador A; Hassannejad N; Narimani M; Sanei MH; Bayat B; Ghazanfari H
Bratisl Lek Listy; 2015; 116(5):296-301. PubMed ID: 25924638
[TBL] [Abstract][Full Text] [Related]
51. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxic T cells expressing the co-stimulatory receptor NKG2 D are increased in cigarette smoking and COPD.
Roos-Engstrand E; Pourazar J; Behndig AF; Blomberg A; Bucht A
Respir Res; 2010 Sep; 11(1):128. PubMed ID: 20863413
[TBL] [Abstract][Full Text] [Related]
53. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.
Song H; Park H; Park G; Kim YS; Lee HK; Jin DH; Kang HS; Cho DH; Hur D
Oncol Rep; 2014 Jul; 32(1):425-30. PubMed ID: 24841552
[TBL] [Abstract][Full Text] [Related]
54. A high frequency of peripheral blood NKG2D+NK and NKT cells in euthyroid patients with new onset hashimoto's thyroiditis--a pilot study.
Guo H; Xu B; Yang X; Wang Y; Liu X; Cui C; Jiang Y
Immunol Invest; 2014; 43(4):312-23. PubMed ID: 24328530
[TBL] [Abstract][Full Text] [Related]
55. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer.
Chen J; Xu H; Zhu XX
Ther Clin Risk Manag; 2016; 12():11-8. PubMed ID: 26730197
[TBL] [Abstract][Full Text] [Related]
56. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
57. Peripheral Foxp3+ regulatory T cells and natural killer group 2, member D expression levels in natural killer cells of patients with colorectal cancer.
Shen Y; Wang Q; Qi Y; Cui B; Zhang Z; Su J; Liu X; Lu C; Ye H; Ju Y; Lu Z
Mol Med Rep; 2014 Aug; 10(2):977-82. PubMed ID: 24819058
[TBL] [Abstract][Full Text] [Related]
58. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.
Holdenrieder S; Eichhorn P; Beuers U; Samtleben W; Stieber P; Nagel D; Peterfi A; Steinle A; Salih HR
Anticancer Res; 2007; 27(4A):2041-5. PubMed ID: 17649819
[TBL] [Abstract][Full Text] [Related]
59. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients.
Peraldi MN; Berrou J; Dulphy N; Seidowsky A; Haas P; Boissel N; Metivier F; Randoux C; Kossari N; Guérin A; Geffroy S; Delavaud G; Marin-Esteban V; Glotz D; Charron D; Toubert A
J Immunol; 2009 Feb; 182(3):1696-705. PubMed ID: 19155520
[TBL] [Abstract][Full Text] [Related]
60. Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function.
Joshi SK; Lang ML
Int Immunopharmacol; 2013 Oct; 17(2):260-6. PubMed ID: 23800654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
